Advertisement
In animal models of inflammation, the anti-inflammatory activity of ARX828is significantly higher than Indomethacin and as effective as Dexamethasone (asteroidal drug), but without the side-effects associated with either of thesedrugs.
Advertisement
The Company has initiated two pivotal animal studies for ARX828 andexpects to receive results from these studies for analysis, by end ofNovember. The Company's goal is to develop ARX828 for the treatment ofRheumatoid Arthritis and Inflammatory Bowel Disease.
About Rheumatoid Arthritis (RA)
There is no treatment currently available to cure RA. The goals oftreatment are to relieve pain, reduce inflammation, slow down joint damage andimprove function. Most RA patients require some form of DMARD--these includemethotrexate, an anti-cancer agent or the TNF-blocking agents such as Enbrel.The TNF-blocking agents only inhibit the inflammatory mediator, TNF, andrequire parenteral administration.
About Inflammatory Bowel Disease
Inflammatory bowel disease encompasses two chronic diseases that causeinflammation of the intestines: ulcerative colitis and Crohn's disease. It isestimated that 1,000,000 Americans suffer from IBD. The primary goal ofcurrent treatment is to reduce and prevent inflammation that triggerssymptoms.
About AlphaRx Inc.
AlphaRx is a specialty pharmaceutical company utilizing proprietarysite-specific nanoparticulate drug delivery systems to develop novelformulations of drugs that are insoluble or poorly soluble in water or haveyet to be administrable to the human body with an acceptable delivery method.The Company also discovers and develops novel, small-molecule drugs for thetreatment of inflammatory diseases and neurodegenerative diseases.
Forward Looking Statements:
This release contains forward-looking statements within the meaning andpursuant to the Safe Harbor provisions of the Securities Litigation Reform Actof 1995 and involve risks and uncertainties that may individually or mutuallyimpact the matters herein described, including but not limited to productdevelopment and acceptance, manufacturing, competition, regulatory and/orother factors, which are outside the control of the companies.
SOURCE AlphaRx Inc.
